| dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
| dc.contributor.author | Herance Camacho, José Raul |
| dc.contributor.author | Velasquez Arevalo, Mayra Alejandra |
| dc.contributor.author | Garcia León, Daniel |
| dc.contributor.author | Aparicio Gomez, Carolina |
| dc.contributor.author | Marès Pagès, Roso |
| dc.contributor.author | Simó Servat, Olga |
| dc.contributor.author | Castell Conesa, Joan |
| dc.contributor.author | Hernández Pascual, Cristina |
| dc.contributor.author | Aguade Bruix, Santiago |
| dc.contributor.author | Simó Canonge, Rafael |
| dc.contributor.author | Paun, Bruno |
| dc.date.accessioned | 2022-12-12T11:03:04Z |
| dc.date.available | 2022-12-12T11:03:04Z |
| dc.date.issued | 2022-01-02 |
| dc.identifier.citation | Herance JR, Simó R, Velasquez MA, Paun B, García-Leon D, Aparicio C, et al. Phenotyping Type 2 Diabetes in Terms of Myocardial Insulin Resistance and Its Potential Cardiovascular Consequences: A New Strategy Based on 18F-FDG PET/CT. J Pers Med. 2022 Jan 2;12:30. |
| dc.identifier.issn | 2075-4426 |
| dc.identifier.uri | https://hdl.handle.net/11351/8647 |
| dc.description | Cardiovascular risk; Myocardial insulin resistance; Type 2 diabetes |
| dc.description.abstract | Background: Systemic insulin resistance is generally postulated as an independent risk factor of cardiovascular events in type 2 diabetes (T2D). However, the role of myocardial insulin resistance (mIR) remains to be clarified. Methods: Two 18F-FDG PET/CT scans were performed on forty-three T2D patients at baseline and after hyperinsulinemic–euglycemic clamp (HEC). Myocardial insulin sensitivity (mIS) was determined by measuring the increment in myocardial 18F-FDG uptake after HEC. Coronary artery calcium scoring (CACs) and myocardial radiodensity (mRD) were assessed by CT. Results: After HEC, seventeen patients exhibited a strikingly enhancement of myocardial 18F-FDG uptake and twenty-six a marginal increase, thus revealing mIS and mIR, respectively. Patients with mIR showed higher mRD (HU: 38.95 [33.81–44.06] vs. 30.82 [21.48–38.02]; p = 0.03) and CACs > 400 (AU: 52% vs. 29%; p = 0.002) than patients with mIS. In addition, HOMA-IR and mIS only showed a correlation in those patients with mIR. Conclusions: 18F-FDG PET combined with HEC is a reliable method for identifying patients with mIR. This subgroup of patients was found to be specifically at high risk of developing cardiovascular events and showed myocardial structural changes. Moreover, the gold-standard HOMA-IR index was only associated with mIR in this subgroup of patients. Our results open up a new avenue for stratifying patients with cardiovascular risk in T2D. |
| dc.language.iso | eng |
| dc.publisher | MDPI |
| dc.relation.ispartofseries | Journal of Personalized Medicine;12 |
| dc.rights | Attribution 4.0 International |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
| dc.source | Scientia |
| dc.subject | Diabetis no-insulinodependent |
| dc.subject | Insulinoresistència |
| dc.subject | Miocardi - Malalties |
| dc.subject.mesh | Diabetes Mellitus, Type 2 |
| dc.subject.mesh | Insulin Resistance |
| dc.subject.mesh | Diabetic Cardiomyopathies |
| dc.title | Phenotyping Type 2 Diabetes in Terms of Myocardial Insulin Resistance and Its Potential Cardiovascular Consequences: A New Strategy Based on 18F-FDG PET/CT |
| dc.type | info:eu-repo/semantics/article |
| dc.identifier.doi | 10.3390/jpm12010030 |
| dc.subject.decs | diabetes mellitus tipo II |
| dc.subject.decs | resistencia a la insulina |
| dc.subject.decs | miocardiopatías diabéticas |
| dc.relation.publishversion | https://doi.org/10.3390/jpm12010030 |
| dc.type.version | info:eu-repo/semantics/publishedVersion |
| dc.audience | Professionals |
| dc.contributor.organismes | Institut Català de la Salut |
| dc.contributor.authoraffiliation | [Herance JR] Grup de Recerca en Imatge Mèdica Molecular, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Unitat Docent de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBERBBN, Instituto de Salud Carlos III, Madrid, Spain. [Simó R, Simó-Servat O, Hernández C] Grup de Recerca en Diabetis i Metabolisme, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d’Endocrinologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBERDEM, Instituto de Salud Carlos III, Madrid, Spain. [Velasquez MA] Grup de Recerca en Diabetis i Metabolisme, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei d’Endocrinologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Paun B, García-Leon D, Aparicio C, Marés R, Castell-Conesa J, Aguadé-Bruix S] Grup de Recerca en Imatge Mèdica Molecular, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Unitat Docent de Medicina Nuclear, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain |
| dc.identifier.pmid | 35055345 |
| dc.identifier.wos | 000746238400001 |
| dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2013-2016/PI16%2F02064 |
| dc.relation.projectid | info:eu-repo/grantAgreement/ES/PE2017-2020/PI20%2F01588 |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess |